DOCS
Doximity, Inc. · Healthcare · Health Information Services
Last
$24.53
−$0.58 (−2.29%) 4:00 PM ET
Prev close $25.10
Open $24.64
Day high $24.76
Day low $24.16
Volume 2,954,980
Avg vol 4,320,758
Mkt cap
$4.53B
P/E ratio
20.44
FY Revenue
$637.78M
EPS
1.20
Gross Margin
89.75%
Sector
Healthcare
AI report sections
DOCS
Doximity, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−36% (Below avg)
Vol/Avg: 0.64×
RSI
25.61 (Oversold)
Oversold (<30)
MACD momentum
Intraday
-0.00 (Weak)
MACD: 0.02 Signal: 0.02
Short-Term
+0.19 (Strong)
MACD: -4.07 Signal: -4.26
Long-Term
-0.26 (Weak)
MACD: -6.69 Signal: -6.43
Intraday trend score 45.00

Latest news

DOCS 12 articles Positive: 4 Neutral: 3 Negative: 5
Positive The Motley Fool • Brett Schafer
Got $50,000? This Unbelievable SaaS Compounder Is Hiding in Plain Sight.

Doximity (DOCS), a social network and software platform for doctors, has fallen 66% over the past year amid software stock selloffs driven by AI disruption fears. Despite the stock decline, the underlying business remains strong with 89.75% gross margins, 38.5% EBIT margins, and a dominant position serving 85% of U.S. physicians. Trading at a P/E of 21, the stock presents a buying opportunity for investors as the company expands into new software tools like DoxGPT.

DOCS SaaS software stocks AI disruption healthcare technology medical professionals pharmaceutical sponsorships profit margins
Sentiment note

Despite a 66% stock decline, the article highlights strong fundamentals including 89.75% gross margins, 38.5% EBIT margins, dominant market position (85% of U.S. physicians), 126 high-value customers, and expansion into new software tools. The stock is presented as undervalued at a P/E of 21, creating a buying opportunity during the software sector selloff.

Negative GlobeNewswire Inc. • Halper Sadeh Llc
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC is investigating whether officers and directors of Doximity Inc. breached their fiduciary duties to shareholders. The firm is seeking long-term shareholders to participate in potential litigation for corporate governance reforms and financial recovery.

DOCS fiduciary duty shareholder investigation corporate governance investor rights securities litigation
Sentiment note

The company is under investigation for potential fiduciary duty breaches by its officers and directors, which raises concerns about corporate governance and management integrity. This typically indicates shareholder concerns and potential misconduct.

Negative GlobeNewswire Inc. • Halper Sadeh Llc
Halper Sadeh LLC Encourages Driven Brand Holdings Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Driven Brands Holdings Inc. and Doximity Inc. breached their fiduciary duties to shareholders. The firm is encouraging long-term shareholders to contact them regarding potential corporate governance reforms and financial recovery options.

DRVN DOCS fiduciary duty breach shareholder investigation corporate governance investor rights securities litigation
Sentiment note

The company is subject to investigation by the same law firm regarding potential breaches of fiduciary duties by officers and directors, suggesting similar governance and misconduct concerns.

Positive The Motley Fool • Josh Kohn-Lindquist
William Blair Dumps $21 Million of Healthcare Platform Doximity Stock

William Blair Investment Management sold 372,184 shares of Doximity (worth ~$21 million) in Q4 2025, reducing its position by 15%. Despite the sale, the author remains bullish on Doximity, citing its reasonable 17x free cash flow valuation, strong physician adoption (85% of U.S. doctors), and upcoming AI monetization opportunities in 2026. The stock has declined 66% year-over-year, partly due to temporary pharma spending delays that are now subsiding.

DOCS NVDA MSFT AAPL Doximity William Blair stock sale healthcare platform
Sentiment note

Despite William Blair's partial sale, the author expresses bullish sentiment on Doximity's fundamentals. The company trades at historically low valuations (17x FCF), maintains strong physician adoption (85% of U.S. doctors), and has near-term catalysts including resolution of pharma spending delays and AI product monetization in 2026. The author views the 66% year-over-year decline as overdone.

Neutral The Motley Fool • Jesterai
Doximity (DOCS) Q1 Revenue Rises 15%

Doximity reported Q1 FY2026 results with revenue of $145.9 million, missing analyst expectations but beating earnings per share estimates. The company raised full-year guidance and showed strong performance in AI tool adoption and workflow solutions.

DOCS healthcare digital platform medical professionals AI earnings workflow tools
Sentiment note

Mixed performance with revenue miss but strong profitability metrics, increased guidance, and significant AI tool adoption. Cautious outlook due to potential upsell variability and macroeconomic uncertainties.

Positive The Motley Fool • Rachel Warren
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Two healthcare stocks, Hims & Hers Health and Doximity, have seen significant stock price growth over the past year, with potential for continued expansion in digital health and professional networking platforms.

HIMS DOCS healthcare digital health stocks investment growth
Sentiment note

Achieved over 100% stock price growth, 20% revenue increase to $570.4 million, 51% net income growth, profitable advertising model for healthcare professionals, and offering comprehensive digital networking tools

Negative GlobeNewswire Inc. • Johnson Fistel, Pllp
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Johnson Fistel is investigating potential legal claims against Doximity, alleging securities fraud involving misrepresentation of user metrics and growth prospects. A court recently denied defendants' motion to dismiss the class action lawsuit.

DOCS securities fraud shareholder rights class action lawsuit user metrics
Sentiment note

The company is facing a securities fraud lawsuit alleging false statements about user engagement, growth prospects, and potential misrepresentation of internal data. The court's denial of the motion to dismiss suggests substantial merit to the plaintiffs' claims.

Neutral GlobeNewswire Inc. • N/A
SHAREHOLDER ALERT: Morris Kandinov Investigating DV, MANH, DOCS, and SEDG; Shareholders are Encouraged to Contact the Firm

Morris Kandinov, a national law firm, is investigating potential breaches of fiduciary duties and other legal violations by DoubleVerify Holdings, Manhattan Associates, Doximity, and SolarEdge Technologies on behalf of their shareholders.

DV MANH DOCS SEDG DoubleVerify Holdings Manhattan Associates Doximity SolarEdge Technologies
Sentiment note

The article states that a securities class action lawsuit against Doximity is proceeding, but does not provide any details about the allegations or the potential impact on the company.

Negative GlobeNewswire Inc. • Johnson Fistel, Pllp
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

DOCS Doximity securities fraud shareholder investigation
Sentiment note

The article mentions that the court has denied the defendants' motion to dismiss a securities fraud class action against Doximity, finding that the plaintiffs have sufficiently alleged that the company made materially false and/or misleading statements and failed to disclose material adverse facts about its business and operations.

Negative The Motley Fool • Matt Frankel
Doximity: Strong Growth but What's Next?

Doximity reported better-than-expected Q4 results, but its guidance for Q1 and the full year fell short of analyst expectations, leading to a 10% drop in the stock price.

DOCS Doximity earnings guidance stock price
Sentiment note

Doximity's guidance for Q1 and the full year was weaker than expected, leading to a 10% drop in the stock price. This suggests the company may be facing challenges in maintaining its momentum as it expands its platform.

Neutral GlobeNewswire Inc. • Researchandmarkets.Com
DBS Group Digital Transformation Strategy Analysis Report 2025: Technology Initiatives, Accelerators, Incubators, and Programs

The report provides insights into DBS Group's digital transformation strategies, innovation programs, and technology initiatives, including partnerships and product launches. It covers the company's banking and financial solutions, priority markets, and estimated ICT budgets.

GPN DOCS DBS Group digital transformation technology initiatives innovation programs banking financial solutions
Sentiment note

The article mentions Doxa as one of the companies involved in DBS Group's technology initiatives, but does not provide any additional details about the nature of their involvement or the impact on DBS Group's operations.

Positive Benzinga • Lekha Gupta
Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

Several large-cap stocks, including Palantir, Doximity, Super Micro Computer, and Spotify, were among the top performers last week, with gains ranging from 13% to 34%. The strong financial results and analyst upgrades contributed to the stock price increases.

PLTR DOCS SMCI AFRM Palantir Super Micro Computer Spotify Doximity
Sentiment note

The company reported better-than-expected Q3 results and issued strong guidance, resulting in a 34.06% increase in the stock price.

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal